


What is claimed is:

1. A compound of formula (I):



and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, and isotopologues thereof,

wherein:

R¹ is substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;

R² is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R³ is substituted or unsubstituted heterocyclyl or substituted or unsubstituted aryl,

and

L is NH or O;

provided

R³ is not pyridyl when L is NH or when R² is pyrazolyl; and


the compound is not

N-methyl-N-[trans-3-[[5-(1-methyl-1H-pyrazol-4-yl)-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]cyclobutyl]-2-propenamide; or

N-methyl-N-[trans-3-[[5-(1-methyl-1H-pyrazol-3-yl)-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]cyclobutyl]-2-propenamide.

2. The compound of claim 1, wherein L is O.
3. The compound of claim 1, wherein R¹ is substituted or unsubstituted alkyl.

4. The compound of claim 1, wherein R^1 is substituted or unsubstituted methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, tert-pentyl, or 2,2-dimethylpropyl.
5. The compound of claim 1, wherein R^1 is substituted or unsubstituted methyl, ethyl, isopropyl, sec-butyl, t-butyl, or 2,2-dimethylpropyl.
6. The compound of claim 3, wherein the alkyl is substituted with one or more -OR or -NR₂, wherein each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl.
7. The compound of claim 1, wherein R^1 is substituted or unsubstituted C₃₋₈ cycloalkyl.
8. The compound of claim 1, wherein R^1 is substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
9. The compound of claim 7, wherein the cycloalkyl is substituted with one or more -CN, halogen, -OR or a substituted or unsubstituted C₁₋₃alkyl, wherein each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl.
10. The compound of claim 1, wherein R^1 is substituted or unsubstituted non-aromatic heterocyclyl.
11. The compound of claim 1, wherein R^1 is substituted or unsubstituted oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, or piperidinyl.
12. The compound of claim 1, wherein R^1 is substituted or unsubstituted C₁₋₈ alkyl,



wherein

each R' is independently -CN, halogen, -OR or C₁₋₃ alkyl;

R' is -H or C₁₋₃ alkyl;

each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl; and

n is 0-2.

13. The compound of claim 1, wherein R² is substituted phenyl.

14. The compound of claim 13, wherein R² is phenyl, substituted with one or more substituted or unsubstituted C₁₋₆ alkyl, halogen, -CN, -OR⁵, -C(=O)NR⁵, -C(=O)(substituted or unsubstituted heterocyclyl), -C(=O)(substituted or unsubstituted alkylheterocyclyl), -NHC(=O)R⁵, -SO₂NR⁵, or substituted or unsubstituted heteroaryl, wherein each R⁵ is independently -H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted alkylheterocyclyl.

15. The compound of claim 13, wherein R² is phenyl, substituted with one or more -(C₁₋₃ alkyl), -(C₁₋₃ alkyl)NR₂, -CF₃, -Cl, -F, -CN, -OCH₃, -OCF₃, -C(=O)NR₂, -C(=O)NR(substituted or unsubstituted cycloalkyl), -C(=O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂OR, -C(=O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂NR₂, -C(=O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂C(=O)NR₂, -C(=O)N(substituted or unsubstituted cycloalkyl)(CH₂)₀₋₂OR, -C(=O)NR(CH₂)₀₋₃(substituted or unsubstituted heterocyclyl), -C(=O)(CH₂)₀₋₃(substituted or unsubstituted heterocyclyl), -C(=NR)NR₂, -NRC(=O)R, -SO₂NR₂, -SO₂R, or substituted or unsubstituted heterocyclyl, wherein each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl.

16. The compound of claim 15, wherein each R is independently -H or -CH₃.

17. The compound of claim 13, wherein R² is phenyl, substituted with one or more -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂NH₂, -CF₃, -Cl, -F, -CN, -OCH₃, -OCF₃, -C(=O)NH₂, -C(=O)NHCH₃, -C(=O)N(CH₃)₂, -C(=O)NC(CH₃)₃, -C(=O)NHCH₂CH₂F, -C(=O)NHCH₂CHF₂, -C(=O)NHCH₂CF₃, -C(=O)NHCH₂CF₂CH₃, -C(=O)NHCH₂CN, -C(=O)N(CH₃)CH₂CN, -C(=O)NHCH₂CH₂CN, -C(=O)N(CH₃)CH₂CH₂CN, -C(=O)NH-cyclobutyl, -C(=O)NH-(hydroxy-cyclobutyl), -C(=O)NH-cyclopentyl, -C(=O)NH-(hydroxy-cyclopentyl), -C(=O)NHCH₂CH₂OH, -C(=O)NHCH₂CH₂OCH₃, -C(=O)N(CH₃)CH₂CH₂OH, -C(=O)N(CH₃)CH₂CH₂OCH₃, -C(=O)NHCH₂CH₂CH₂OH, -C(=O)N(CH₃)CH₂CH₂CH₂OCH₃, -C(=O)NHCH₂CH(CH₃)OH, -C(=O)NHCH₂C(CH₃)₂OH, -C(=O)NHCH(CH₃)CH₂OH, -C(=O)NHC(CH₃)₂CH₂OH,

-C(=O)NHCH₂CH₂NH₂, -C(=O)NHCH₂CH₂NH(CH₃), -C(=O)NHCH₂CH₂N(CH₃)₂,
 -C(=O)NHCH₂C(=O)NH₂, -C(=O)N(CH₃)CH₂C(=O)NH₂, -C(=O)NHCH₂CH₂C(=O)NH₂,
 -C(=O)N(CH₃)CH₂CH₂C(=O)NH₂, -C(=O)N(cyclopropyl)CH₂CH₂OH, -C(=O)NH-oxetanyl,
 -C(=O)N(CH₃)-oxetanyl, -C(=O)NH-(methyl-oxetanyl), -C(=O)NH-azetidiny,
 -C(=O)NH-(methy lazetidiny), -C(=O)NH-(1-acetylazetidiny), -C(=O)NH-pyrrolidyl,
 -C(=O)NH-piperidyl, -C(=O)NH-tetrahydrofuranyl, -C(=O)N(CH₃)-tetrahydrofuranyl,
 -C(=O)NH-tetrahydropyranyl, -C(=O)N(CH₃)-tetrahydropyranyl, -C(=O)NHCH₂-oxetanyl,
 -C(=O)N(CH₃)CH₂-oxetanyl, -C(=O)NHCH₂-(methyl-oxetanyl), -C(=O)N(CH₃)CH₂-(methyl-oxetanyl),
 -C(=O)NHCH₂-tetrahydrofuranyl, -C(=O)NHCH₂-tetrahydropyranyl,
 -C(=O)NHCH₂-dioxanyl, -C(=O)aziridiny, -C(=O)(methyl-aziridiny),
 -C(=O)(dimethyl-aziridiny), -C(=O)(hydroxymethyl-aziridiny), -C(=O)azetidiny,
 -C(=O)pyrrolidiny, -C(=O)(hydroxyl-pyrrolidiny), -C(=O)(hydroxyl, methoxypyrrolidiny),
 -C(=O)(dimethoxypyrrolidiny), -C(=O)morpholinyl, -C(=O)piperazinyl,
 -C(=O)(methylpiperazinyl), -C(=O)(hydroxy-piperidyl), -C(=O)(fluoropiperidiny),
 -C(=O)(methoxy-piperidyl), -C(=NH)NH₂, -NHC(=O)CH₃, -SO₂NHCH₃, -SO₂CH₃, or
 substituted or unsubstituted pyrazolyl.

18. The compound of claim 13, wherein R² is phenyl, substituted with one or more
 -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂NH₂, -CF₃, -Cl, -F, -CN, -OCH₃, -OCF₃,
 -C(=O)NH₂, -C(=O)NHCH₃, -C(=O)N(CH₃)₂, -C(=O)NC(CH₃)₃, -C(=O)NHCH₂CH₂F,
 -C(=O)NHCH₂CF₂CH₃, -C(=O)N(CH₃)CH₂CN, -C(=O)N(CH₃)CH₂CH₂CN,
 -C(=O)NH-(3-hydroxy-cyclobutyl), -C(=O)NH-cyclopentyl,
 -C(=O)NH-(2-hydroxycyclopentyl), -C(=O)NHCH₂CH₂OH, -C(=O)NHCH₂CH₂OCH₃,
 -C(=O)N(CH₃)CH₂CH₂OH, -C(=O)N(CH₃)CH₂CH₂OCH₃, -C(=O)NHCH₂CH₂CH₂OH,
 -C(=O)N(CH₃)CH₂CH₂CH₂OH, -C(=O)NHCH₂CH(CH₃)OH, -C(=O)NHCH₂C(CH₃)₂OH,
 -C(=O)NHCH(CH₃)CH₂OH, -C(=O)NHC(CH₃)₂CH₂OH, -C(=O)NHCH₂CH₂NH₂,
 -C(=O)NHCH₂CH₂NH(CH₃), -C(=O)NHCH₂CH₂N(CH₃)₂, -C(=O)N(CH₃)CH₂C(=O)NH₂,
 -C(=O)N(CH₃)CH₂CH₂C(=O)NH₂, -C(=O)N(cyclopropyl)CH₂CH₂OH, -C(=O)NH-oxetanyl,
 -C(=O)N(CH₃)-oxetanyl, -C(=O)NH-(3-methyl-oxetanyl), -C(=O)NH-(1-methylazetidiny),
 -C(=O)NH-(1-acetylazetidiny), -C(=O)NH-piperidyl, -C(=O)NH-tetrahydrofuranyl,
 -C(=O)NH-tetrahydropyranyl, -C(=O)N(CH₃)-tetrahydropyranyl, -C(=O)NHCH₂-oxetanyl,
 -C(=O)N(CH₃)CH₂-(3-methyl-oxetanyl), -C(=O)NHCH₂-tetrahydrofuranyl,

-C(=O)NHCH₂-tetrahydropyranyl, -C(=O)NHCH₂-dioxanyl, -C(=O)aziridinyl, -C(=O)(2-methyl-aziridinyl), -C(=O)(2,2-dimethyl-aziridinyl), -C(=O)(2-(hydroxymethyl)aziridinyl), -C(=O)azetidiny, -C(=O)pyrrolidinyl, -C(=O)(3-hydroxy-4-methoxypyrrolidinyl), -C(=O)(3,4-dimethoxypyrrolidinyl), -C(=O)morpholinyl, -C(=O)piperazinyl, -C(=O)(4-methylpiperazinyl), -C(=O)(4-hydroxy-piperidyl), -C(=O)(4,4-difluoropiperidinyl), -(C=O)(4-methoxy-piperidyl), -C(=NH)NH₂, -NHC(=O)CH₃, -SO₂NHCH₃, -SO₂CH₃, or substituted or unsubstituted pyrazolyl.

19. The compound of claim 1, wherein R² is substituted or unsubstituted pyrazolyl, substituted or unsubstituted pyridyl, substituted or unsubstituted indazolyl or substituted or unsubstituted isoindolinone.

20. The compound of claim 19, wherein R² is substituted with one or more halogen, substituted or unsubstituted (C₁₋₄)alkyl, -OR, -C(=O)NR₂, or substituted or unsubstituted heterocyclyl, wherein each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl.

21. The compound of claim 1, wherein R³ is substituted or unsubstituted heterocyclyl.

22. The compound of claim 21, wherein the heterocyclyl is substituted or unsubstituted pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, benzotriazolyl, indazolyl, indolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzoxazolonyl, benzoxadiazolyl, benzimidazolyl, or quinolyl.

23. The compound of claim 21, wherein the heterocyclyl is substituted with one or more substituents selected from substituted or unsubstituted (C₁₋₄)alkyl, halogen, -OR, -CN, -NR₂, -C(=O)NR₂, -NRC(=O)R, or substituted or unsubstituted triazolyl, wherein each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl.

24. The compound of claim 21, wherein the heterocyclyl is substituted with one or more substituents selected from -CH₃, -CH(CH₃)₂, -F, -Cl, -OH, -OCH₃, -OCH₂CH₃, -CN, -NH₂, -NHCH₃, -N(CH₃)₂, -C(=O)NH(CH₃), -NHC(=O)CH₃, or substituted or unsubstituted triazolyl.

25. The compound of claim 1, wherein R³ is substituted or unsubstituted aryl.

26. The compound of claim 1, wherein R³ is substituted or unsubstituted phenyl.

27. The compound of claim 26, wherein the phenyl is substituted with one or more substituents selected from substituted or unsubstituted C₁₋₄ alkyl, halogen, -CN, -OR, -NR₂,

-NRSO₂R', -NR(C=O)NR₂, -NR(C=O)R', -COOR, -(C=O)NR₂, -C(=N)NR₂, -SO₂R', or substituted or unsubstituted heteroaryl, wherein each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl, and R' is C₁₋₃ alkyl.

28. The compound of claim 26, wherein the phenyl is substituted with one or more substituents selected from -CH₃, -CH₂OH, -CH(OH)CH₃, -C(CH₃)₂OH, -CN, -F, -Cl, -OH, -OCH₃, -NH₂, -N(CH₃)₂, -NHSO₂CH₃, -NH(C=O)NH₂, -NH(C=O)CH₃, -COOCH₃, -(C=O)NHCH₃, -C(=NH)NH₂, -SO₂CH₃, substituted or unsubstituted triazolyl, substituted or unsubstituted pyrazolyl, or substituted or unsubstituted imidazolyl.

29. The compound of claim 1, wherein the compound is selected from Table 1, or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, or isotopologue thereof.


30. The compound of claim 1 or claim 29, wherein the compound at a concentration of 10 μM inhibits triple negative breast cancer cell proliferation by at least about 50%.

31. A pharmaceutical composition comprising an effective amount of a compound of claim 1 or claim 29, or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, or isotopologue thereof, and a pharmaceutically acceptable carrier, excipient or vehicle.

32. A method for the treatment or prevention of breast cancer, the methods comprising administering to a subject in need thereof an effective amount of a compound of claim 1 or claim 29.

Claims

1. A compound of formula (I):



and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, and isotopologues thereof,

wherein:

R¹ is substituted or unsubstituted C₁₋₈ alkyl, substituted or unsubstituted C₃₋₈ cycloalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;

R² is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R³ is substituted or unsubstituted heterocyclyl or substituted or unsubstituted aryl,

and

L is NH or O;

provided

R³ is not pyridyl when L is NH or when R² is pyrazolyl; and

the compound is not

N-methyl-N-[trans-3-[[5-(1-methyl-1H-pyrazol-4-yl)-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]cyclobutyl]-2-propenamide; or

N-methyl-N-[trans-3-[[5-(1-methyl-1H-pyrazol-3-yl)-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]cyclobutyl]-2-propenamide.


2. The compound of claim 1, wherein L is O.

3. The compound of claim 1, wherein R¹ is substituted or unsubstituted alkyl.

4. The compound of claim 1, wherein R¹ is substituted or unsubstituted methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, tert-pentyl, or 2,2-dimethylpropyl.

5. The compound of claim 1, wherein R¹ is substituted or unsubstituted methyl, ethyl, isopropyl, sec-butyl, t-butyl, or 2,2-dimethylpropyl.

6. The compound of claim 3, wherein the alkyl is substituted with one or more -OR or -NR₂, wherein each R is independently -H or substituted or unsubstituted (C₁₋₄) alkyl.
7. The compound of claim 1, wherein R¹ is substituted or unsubstituted C₃₋₈ cycloalkyl.
8. The compound of claim 1, wherein R¹ is substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
9. The compound of claim 7, wherein the cycloalkyl is substituted with one or more -CN, halogen, -OR or a substituted or unsubstituted C₁₋₃ alkyl, wherein each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl.
10. The compound of claim 1, wherein R¹ is substituted or unsubstituted non-aromatic heterocyclyl.
11. The compound of claim 1, wherein R¹ is substituted or unsubstituted oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, or piperidiny.
12. The compound of claim 1, wherein R¹ is substituted or unsubstituted C₁₋₈ alkyl,



wherein

each R' is independently -CN, halogen, -OR or C₁₋₃ alkyl;

R'' is -H or C₁₋₃ alkyl;

each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl; and

n is 0-2.

13. The compound of claim 1, wherein R² is substituted phenyl.
14. The compound of claim 13, wherein R² is phenyl, substituted with one or more substituted or unsubstituted C₁₋₆ alkyl, halogen, -CN, -OR⁵, -C(=O)NR⁵₂, -C(=O)(substituted or unsubstituted heterocyclyl), -C(=O)(substituted or unsubstituted alkylheterocyclyl), -NHC(=O)R⁵, -SO₂NR⁵₂, or substituted or unsubstituted heteroaryl, wherein each R⁵ is independently -H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted alkylheterocyclyl.
15. The compound of claim 13, wherein R² is phenyl, substituted with one or more -(C₁₋₃ alkyl), -(C₁₋₃ alkyl)NR₂, -CF₃, -Cl, -F, -CN, -OCH₃, -OCF₃, -C(=O)NR₂,

-C(=O)NR(substituted or unsubstituted cycloalkyl), -C(=O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂OR,

-C(=O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂NR₂, -C(=O)NR(CH₂)₀₋₂CR₂(CH₂)₀₋₂C(=O)NR₂,

-C(=O)N(substituted or unsubstituted cycloalkyl)(CH₂)₀₋₂OR, -C(=O)NR(CH₂)₀₋₃(substituted or unsubstituted heterocyclyl), -C(=O)(CH₂)₀₋₃(substituted or unsubstituted heterocyclyl),

-C(=NR)NR₂, -NRC(=O)R, -SO₂NR₂, -SO₂R, or substituted or unsubstituted heterocyclyl, wherein each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl.

16. The compound of claim 15, wherein each R is independently -H or -CH₃.

17. The compound of claim 13, wherein R² is phenyl, substituted with one or more -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂NH₂, -CF₃, -Cl, -F, -CN, -OCH₃, -OCF₃, -C(=O)NH₂, -C(=O)NHCH₃, -C(=O)N(CH₃)₂, -C(=O)NC(CH₃)₃, -C(=O)NHCH₂CH₂F,

-C(=O)NHCH₂CHF₂, -C(=O)NHCH₂CF₃, -C(=O)NHCH₂CF₂CH₃, -C(=O)NHCH₂CN,

-C(=O)N(CH₃)CH₂CN, -C(=O)NHCH₂CH₂CN, -C(=O)N(CH₃)CH₂CH₂CN,

-C(=O)NH-cyclobutyl, -C(=O)NH-(hydroxy-cyclobutyl), -C(=O)NH-cyclopentyl,

-C(=O)NH-(hydroxy-cyclopentyl), -C(=O)NHCH₂CH₂OH, -C(=O)NHCH₂CH₂OCH₃,

-C(=O)N(CH₃)CH₂CH₂OH, -C(=O)N(CH₃)CH₂CH₂OCH₃, -C(=O)NHCH₂CH₂CH₂OH,

-C(=O)N(CH₃)CH₂CH₂CH₂OH, -C(=O)N(CH₃)CH₂CH₂CH₂OCH₃, -C(=O)NHCH₂CH(CH₃)OH, -C(=O)NHCH₂C(CH₃)₂OH, -C(=O)NHCH(CH₃)CH₂OH, -C(=O)NHC(CH₃)₂CH₂OH,

-C(=O)NHCH₂CH₂NH₂, -C(=O)NHCH₂CH₂NH(CH₃), -C(=O)NHCH₂CH₂N(CH₃)₂,

-C(=O)NHCH₂C(=O)NH₂, -C(=O)N(CH₃)CH₂C(=O)NH₂, -C(=O)NHCH₂CH₂C(=O)NH₂, -C(=O)N(CH₃)CH₂CH₂C(=O)NH₂, -C(=O)N(cyclopropyl)CH₂CH₂OH, -C(=O)NH-oxetanyl, -C(=O)N(CH₃)-oxetanyl, -C(=O)NH-(methyl-oxetanyl), -C(=O)NH-azetidiny,

-C(=O)NH-(methylazetidiny), -C(=O)NH-(1-acetylazetidiny), -C(=O)NH-pyrrolidyl, -C(=O)NH-piperidyl, -C(=O)NH-tetrahydrofuranyl, -C(=O)N(CH₃)-tetrahydrofuranyl, -C(=O)NH-tetrahydropyranyl, -C(=O)N(CH₃)-tetrahydropyranyl, -C(=O)NHCH₂-oxetanyl, -C(=O)N(CH₃)CH₂-oxetanyl, -C(=O)NHCH₂-(methyl-oxetanyl), -C(=O)N(CH₃)CH₂-(methyl-oxetanyl), -C(=O)NHCH₂-tetrahydrofuranyl, -C(=O)NHCH₂-tetrahydropyranyl,

-C(=O)NHCH₂-dioxanyl, -C(=O)aziridiny, -C(=O)(methyl-aziridiny),

-C(=O)(dimethyl-aziridiny), -C(=O)(hydroxymethyl-aziridiny), -C(=O)azetidiny,

-C(=O)pyrrolidiny, -C(=O)(hydroxyl-pyrrolidiny), -C(=O)(hydroxyl, methoxypyrrolidiny), -C(=O)(dimethoxypyrrolidiny), -C(=O)morpholinyl, -C(=O)piperazinyl,

-C(=O)(methylpiperazinyl), -C(=O)(hydroxy-piperidyl), -C(=O)(fluoropiperidyl),

-C(=O)(methoxy-piperidyl), -C(=NH)NH₂, -NHC(=O)CH₃, -SO₂NHCH₃, -SO₂CH₃, or substituted or unsubstituted pyrazolyl.

18. The compound of claim 13, wherein R² is phenyl, substituted with one or more -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂NH₂, -CF₃, -Cl, -F, -CN, -OCH₃, -OCF₃, -C(=O)NH₂, -C(=O)NHCH₃, -C(=O)N(CH₃)₂, -C(=O)NC(CH₃)₃, -C(=O)NHCH₂CH₂F, -C(=O)NHCH₂CF₂CH₃, -C(=O)N(CH₃)CH₂CN, -C(=O)N(CH₃)CH₂CH₂CN,

-C(=O)NH-(3-hydroxy-cyclobutyl), -C(=O)NH-cyclopentyl,

-C(=O)NH-(2-hydroxycyclopentyl), -C(=O)NHCH₂CH₂OH, -C(=O)NHCH₂CH₂OCH₃, -C(=O)N(CH₃)CH₂CH₂OH, -C(=O)N(CH₃)CH₂CH₂OCH₃, -C(=O)NHCH₂CH₂CH₂OH, -C(=O)N(CH₃)CH₂CH₂CH₂OH, -C(=O)NHCH₂CH(CH₃)OH, -C(=O)NHCH₂C(CH₃)₂OH, -C(=O)NHCH(CH₃)CH₂OH, -C(=O)NHC(CH₃)₂CH₂OH, -C(=O)NHCH₂CH₂NH₂,

-C(=O)NHCH₂CH₂NH(CH₃), -C(=O)NHCH₂CH₂N(CH₃)₂, -C(=O)N(CH₃)CH₂C(=O)NH₂, -C(=O)N(CH₃)CH₂CH₂C(=O)NH₂, -C(=O)N(cyclopropyl)CH₂CH₂OH, -C(=O)NH-oxetanyl, -C(=O)N(CH₃)-oxetanyl, -C(=O)NH-(3-methyl-oxetanyl), -C(=O)NH-(1-methylazetidiny), -C(=O)NH-(1-acetylazetidiny), -C(=O)NH-piperidyl, -C(=O)NH-tetrahydrofuranyl,

-C(=O)NH-tetrahydropyranyl, -C(=O)N(CH₃)-tetrahydropyranyl, -C(=O)NHCH₂-oxetanyl, -C(=O)N(CH₃)CH₂-(3-methyl-oxetanyl), -C(=O)NHCH₂-tetrahydrofuranyl,

-C(=O)NHCH₂-tetrahydropyranyl, -C(=O)NHCH₂-dioxanyl, -C(=O)aziridiny,

-C(=O)(2-methyl-aziridiny), -C(=O)(2,2-dimethyl-aziridiny),

-C(=O)(2-(hydroxymethyl)aziridiny), -C(=O)azetidiny, -C(=O)pyrrolidiny,

-C(=O)(3-hydroxy-4-methoxypyrrolidiny), -C(=O)(3,4-dimethoxypyrrolidiny),

-C(=O)morpholiny, -C(=O)piperaziny, -C(=O)(4-methylpiperaziny),

-C(=O)(4-hydroxy-piperidyl), -C(=O)(4,4-difluoropiperidiny), -C(=O)(4-methoxy-piperidyl), -C(=NH)NH₂, -NHC(=O)CH₃, -SO₂NHCH₃, -SO₂CH₃, or substituted or unsubstituted pyrazolyl.

19. The compound of claim 1, wherein R² is substituted or unsubstituted pyrazolyl, substituted or unsubstituted pyridyl, substituted or unsubstituted indazolyl or substituted or unsubstituted isoindolinone.

20. The compound of claim 19, wherein R² is substituted with one or more halogen, substituted or unsubstituted (C₁₋₄)alkyl, -OR, -C(=O)NR₂, or substituted or unsubstituted heterocyclyl, wherein each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl.

21. The compound of claim 1, wherein R³ is substituted or unsubstituted heterocyclyl.

22. The compound of claim 21, wherein the heterocyclyl is substituted or

unsubstituted pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, pyridaziny, pyrimidyl, pyraziny, benzotriazolyl, indazolyl, indolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzoxazolonyl, benzoxadiazolyl, benzimidazolyl, or quinolyl.

23. The compound of claim 21, wherein the heterocyclyl is substituted with one or more substituents selected from substituted or unsubstituted (C₁₋₄)alkyl, halogen, -OR, -CN, -NR₂, -C(=O)NR₂, -NRC(=O)R, or substituted or unsubstituted triazolyl, wherein each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl.

24. The compound of claim 21, wherein the heterocyclyl is substituted with one or more substituents selected from -CH₃, -CH(CH₃)₂, -F, -Cl, -OH, -OCH₃, -OCH₂CH₃, -CN, -NH₂, -NHCH₃, -N(CH₃)₂, -C(=O)NH(CH₃), -NHC(=O)CH₃, or substituted or unsubstituted triazolyl.
25. The compound of claim 1, wherein R³ is substituted or unsubstituted aryl.
26. The compound of claim 1, wherein R³ is substituted or unsubstituted phenyl.
27. The compound of claim 26, wherein the phenyl is substituted with one or more substituents selected from substituted or unsubstituted C₁₋₄ alkyl, halogen, -CN, -OR, -NR₂, -NRSO₂R', -NR(C=O)NR₂, -NR(C=O)R', -COOR, -(C=O)NR₂, -C(=N)NR₂, -SO₂R', or substituted or unsubstituted heteroaryl, wherein each R is independently -H or substituted or unsubstituted (C₁₋₄)alkyl, and R' is C₁₋₃ alkyl.
28. The compound of claim 26, wherein the phenyl is substituted with one or more substituents selected from -CH₃, -CH₂OH, -CH(OH)CH₃, -C(CH₃)₂OH, -CN, -F, -Cl, -OH, -OCH₃, -NH₂, -N(CH₃)₂, -NHSO₂CH₃, -NH(C=O)NH₂, -NH(C=O)CH₃, -COOCH₃, -(C=O)NHCH₃, -C(=NH)NH₂, -SO₂CH₃, substituted or unsubstituted triazolyl, substituted or unsubstituted pyrazolyl, or substituted or unsubstituted imidazolyl.
29. The compound of claim 1, wherein the compound is selected from Table 1, or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, or isotopologue thereof.
30. The compound of claim 1 or claim 29, wherein the compound at a concentration of 10 μM inhibits triple negative breast cancer cell proliferation by at least about 50%.
31. A pharmaceutical composition comprising an effective amount of a compound of claim 1 or claim 29, or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, or isotopologue thereof, and a pharmaceutically acceptable carrier, excipient or vehicle.
32. Use of a compound according to claims 1 or claim 29 in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of breast cancer.